A Randomized, Open-label, Four-Way Crossover Study to Compare the Bioavailability of a Single Dose of Epanova or Lovaza After a Low-Fat and High-Fat Meal.

Trial Profile

A Randomized, Open-label, Four-Way Crossover Study to Compare the Bioavailability of a Single Dose of Epanova or Lovaza After a Low-Fat and High-Fat Meal.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2015

At a glance

  • Drugs Omega-3 carboxylic acids (Primary) ; Omega-3-acid ethyl esters
  • Indications Crohn's disease; Hypertriglyceridaemia
  • Focus Pharmacokinetics
  • Acronyms ECLIPSE
  • Most Recent Events

    • 10 Jan 2012 Long-term (2-week) bioavailability data were presented at the J.P. Morgan Healthcare Conference.
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 17 May 2011 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top